Aurobindo Pharma’s arm’s manufacturing unit gets 'official action indicated' status by USFDA

27 May 2024 Evaluate

The United States Food and Drug Administration (USFDA) has determined the inspection classification status to Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ unit III, formulation manufacturing facility situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana as ‘Official Action Indicated (OAI)’. The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

USFDA had conducted an inspection at said facility from January 22, 2024 to February 02, 2024.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1240.70 -14.70 (-1.17%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.